¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"B cell differentiation/growth factors"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡¼ºÀåÀÎÀÚ, Ç÷¼ÒÆÇ±â¿ø¼ºÀåÀÎÀÚ
  • specific growth rate
    ƯÀÌÁõ½Ä·ü, ƯÀ̼ºÀå·ü
  • synchronous growth
    µ¿Á¶Áõ½Ä
  • single-step growth curve
    ÀÏȸÁõ½Ä°î¼±
  • vascular endothelial growth factor
    Ç÷°ü³»ÇǼºÀåÀÎÀÚ
  • acantholytic cell
    °¡½Ã¼¼Æ÷ºÐ¸®¼¼Æ÷
  • angioimmunoblastic T-cell lymphoma
    Ç÷°ü¸é¿ª¸ð±¸T¼¼Æ÷¸²ÇÁÁ¾
  • annular elastotic giant cell granuloma
    °í¸®Åº·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾, ȯ»óź·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾
  • accessory cell
    º¸Á¶¼¼Æ÷, µ¡¼¼Æ÷
  • antibody-dependent cell-mediated cytotoxicity
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • antibody-producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
  • antigen-presenting cell
    Ç׿øÁ¦½Ã¼¼Æ÷
  • antigen-reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷
  • antigen-recognizing cell
    Ç׿øÀÎÁö¼¼Æ÷
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • stellate cell
    º°¼¼Æ÷
  • stem cell
    Áٱ⼼Æ÷
  • supporting cell
    ¹öÆÀ¼¼Æ÷
  • sustentacular cell
    (¢¡supporting cell) ¹öÆÀ¼¼Æ÷
  • target cell
    Ç¥Àû¼¼Æ÷
  • transitional cell
    ÀÌÇ༼Æ÷
  • transitional cell carcinoma
    ÀÌÇ༼Æ÷¾ÏÁ¾
  • cell line
    ¼¼Æ÷ÁÖ
  • giant cell pneumonia
    °Å´ë¼¼Æ÷Æó·Å
  • giant cell tumor
    °Å´ë¼¼Æ÷Á¾
  • granular cell tumor
    °ú¸³¼¼Æ÷Á¾¾ç
  • granulosa cell tumor
    °ú¸³Ãþ¼¼Æ÷Á¾¾ç
  • sickle cell trait
    ³´¼¼Æ÷¼ÒÁú, ³´ÀûÇ÷±¸Çü¼º¼ÒÁú
  • packed cell volume
    ÃæÀü¼¼Æ÷¿ëÀû, ³óÃ༼Æ÷¿ëÀû
  • red cell distribution width
    ÀûÇ÷±¸ºÐÆ÷Æø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • physical growth
    ½Åü¹ßÀ°
  • remodeling growth
    ÀçÇü¼º¼ºÀå
  • synchronous growth
    µ¿Á¶Áõ½Ä
  • trajectory growth
    Á÷±³Àý¼±¼ºÀå
  • intrauterine growth retardation
    Àڱ󻼺ÀåÁö¿¬
  • maximal growth rate
    ÃÖ´ëÁõ½Ä·ü
  • specific growth rate
    ƯÀÌÁõ½Ä·ü
  • acantholytic cell
    °¡½Ã¼¼Æ÷ÇØ¸®¼¼Æ÷
  • accessory cell
    º¸Á¶¼¼Æ÷, µ¡¼¼Æ÷
  • acidophilic cell
    È£»ê¼º¼¼Æ÷
  • acinar cell
    »ù²Ê¸®¼¼Æ÷
  • acinic cell carcinoma
    »ù²Ê¸®¼¼Æ÷¾ÏÁ¾, ¼¼¿±¼¼Æ÷¾ÏÁ¾
  • amacrine cell
    ¹«Ãà»è¼¼Æ÷
  • ameboid cell
    ¾Æ¸Þ¹Ù¸ð¾ç¼¼Æ÷
  • annular elastotic giant cell granuloma
    °í¸®Åº·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾, ȯ»óź·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • growth factor
    Áõ½ÄÀÎÀÚ
  • growth factor
    ¼ºÀå ÀÎÀÚ(à÷íþ ì×í­)
  • growth failure
    ¼ºÀåºÎÀü(à÷íþÝÕîï).
  • growth form
    ¼ºÀåÇü(¡­úþ).
  • growth fraction
    Áõ½ÄºÐȹ
  • growth hormone
    ¼ºÀåÈ£¸£¸ó
  • growth hormone
    ¼ºÀåÈ£¸£¸ó(à÷íþ¡­)
  • growth hormone =GH
    ¼ºÀå(à÷íþ)È£¸£¸ó.
  • growth hormone =GH
    ¼ºÀåÈ£¸£¸ó.
  • growth hormone assay
    ¼ºÀåÈ£¸£¸óÃøÁ¤
  • growth hormone-releasing factor
    ¼ºÀåÈ£¸£¸óÀ¯¸®ÀÎÀÚ<--¹æÃâÀÎÀÚ>
  • growth inhibitor
    ¼ºÀå<¹ßÀ°>¾ïÁ¦¹°Áú.
  • growth line
    ¼ºÀå¼±(¡­àÊ).
  • growth of jaw
    ¾Ç¼ºÀå.
  • growth onset type diabetes
    Ãʱâ´ç´¢º´.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • exponential growth rate
    ´ë¼öÁõ½Ä·ü, Áö¼öÁõ½Ä·ü
  • exponential phase of growth
    ´ë¼öÁõ½Ä±â, °¡¼Ó¼ºÀå±â.
  • face growth
  • fetal growth retardation
    ÅÂ¾Æ ¹ßÀ° Áö¿¬, ÅÂ¾Æ ¼ºÀå Áö¿¬
  • fibroblast growth factor
    ¼¶À¯¸ð¼¼Æ÷ ¼ºÀåÀÎÀÚ(¡­à÷íþì×í­)
  • fibroblast growth factor(FGF)
    ¼¶À¯¾Æ¼¼Æ÷ ¼ºÀåÀÎÀÚ
  • grain growth
    ÀÔÀÚÀÇ ¼ºÀå.
  • growth
    ¼ºÀå, Áõ½Ä
  • growth abnormality
    ¹ßÀ°ÀÌ»ó.
  • growth abnormality
    ¼ºÀåÀÌ»ó
  • growth acceleration
    ¼ºÀå<Áõ½Ä>°¡¼ÓµµÇö»ó.
  • growth channels
  • growth chart
    ¼ºÀ嵵ǥ(à÷íþÓñøú).
  • growth chart
    ¼ºÀ嵵ǥ(ËÛËöËÀ̰).
  • growth cone
    ¼ºÀå¿ø»Ô
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • Nonfenestrated endothelial cell
    ¹Îâ³»ÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¹«Ã¢³»ÇǼ¼Æ÷
  • Basket cell
    ¹Ù±¸´Ï¼¼Æ÷
    [¿¾ ¿ë¾î] ³ó¼¼Æ÷
  • Outer pillar cell
    ¹Ù±ù±âµÕ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ÜÁÖ¼¼Æ÷
  • Outer sustentacular cell
    ¹Ù±ù¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ÜÁöÁÖ¼¼Æ÷
  • Outer phalangeal cell of Deiters
    ¹Ù±ù¼Õ°¡¶ô¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ÜÁö»ó¼¼Æ÷
  • Outer hair cell
    ¹Ù±ùÅм¼Æ÷
    [¿¾ ¿ë¾î] ¿ÜÀ¯¸ð¼¼Æ÷
  • Basal epithelial cell
    ¹Ù´Ú»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ±âÀúÃþ»óÇǼ¼Æ÷
  • Basal cell
    ¹Ù´Ú¼¼Æ÷
    [¿¾ ¿ë¾î] ±âÀú¼¼Æ÷
  • Fusiform myoepithelial cell
    ¹æÃß±ÙÀ°»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¹æÃß»ó±Ù»óÇǼ¼Æ÷
  • Fusiform endothelial cell
    ¹æÃß³»ÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¹æÃß»ó³»ÇǼ¼Æ÷
  • Sustentacular cell
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁÖ¼¼Æ÷
  • Parietal cell
    º®¼¼Æ÷
    [¿¾ ¿ë¾î] º®¼¼Æ÷
  • Stellate myoepithelial cell
    º°±ÙÀ°»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¼º»ó±Ù»óÇǼ¼Æ÷
  • Stellate cell
    º°¼¼Æ÷
    [¿¾ ¿ë¾î] ¼º»ó¼¼Æ÷
  • Cell of parathyroid gland
    ºÎ°©»ó»ù¼¼Æ÷
    [¿¾ ¿ë¾î] ºÎ°©»ó¼±¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • cell-free protein synthesis
    ¹«¼¼Æ÷´Ü¹éÁúÇÕ¼º(Ùíá¬øàÓ±ÛÜòõùêà÷)
  • cell-free system
    ¹«¼¼Æ÷(Ùíá¬øà)½Ã½ºÅÛ
  • cell fusion
    ¼¼Æ÷À¶ÇÕ(á¬øàë×ùê)
  • cell hybridization
    ¼¼Æ÷(á¬øà) Æ¢±âÇü¼º(û¡à÷)
  • cell line
    ¼¼Æ÷ÁÖ(á¬øàñ»)
  • cell-mediated immunity
    ¼¼Æ÷¸Å°³¸é¿ª(á¬øàØÚË¿Øóæ¹)
  • cell membrane
    ¼¼Æ÷¸· (á¬øàØ¯)
  • cell strain
    ¼¼Æ÷ÁÖ(á¬øàñ»)
  • cell wall
    ¼¼Æ÷º®(á¬øàÛú)
  • centrifuge cell
    ¿ø½ÉºÐ¸®½Ç(êÀãýÝÂ×îãø)
  • competent cell
    Àû°Ý¼¼Æ÷(îêÌ«á¬øà)
  • constitutive secretory cell
    ±¸¼º¼º ºÐºñ¼¼Æ÷(ϰà÷àõÝÂÝôá¬øà)
  • continuous cell line
    "Áö¼Ó¼¼Æ÷ÁÖ(ò¥áÙá¬øàñ»), (ÔÒ) established cell line"
  • COS cell
    COS ¼¼Æ÷(á¬øà)
  • cytotoxic T cell
    ¼¼Æ÷µ¶¼º(á¬øàÔ¸àõ) T ¼¼Æ÷(á¬øà)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • small cleaved cell
    ¼ÒºÐÇÒ¼¼Æ÷
  • spindle cell
    ¹æÃ߻󼼯÷
  • squamous cell carcinoma
    ÆíÆò¼¼Æ÷¾ÏÁ¾
  • stem cell
    °£¼¼Æ÷
  • stromal cell
    °£Áú¼¼Æ÷
  • T cell ¡ìthymus derived lymphocyte¡í
    T¼¼Æ÷ ¡ì Èä¼±À¯·¡ ¸²ÇÁ±¸¡í
  • tumor cell
    Á¾¾ç¼¼Æ÷
  • white blood cell
    ¹éÇ÷±¸
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
CD Cluster of differentiation
ADRP adipose differentiation-related protein
DA dark adaptation; dark agouti [rat]; daunomycin; degenerative arthritis; delayed action; Dental Assis...
ED early-decision [applicant]; early differentiation; ectodermal dysplasia; ectopic depolarization; eff...
IDL Index to Dental Literature; interface definition language; intermediate density lipoprotein; interme...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
NDF Neu differentiation factor
ODF Osteoclast differentiation factor
SCD Sister chromatid differentiation
TRD Temporal Response Differentiation
AEF Allogeneic effect factors
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • anterior horn cell
    Àü°¢ ¼¼Æ÷
  • antibody dependent cell mediated cytotoxicity
    Ç×ü ÀÇÁ¸ ¼¼Æ÷ ¸Å°³ ¼¼Æ÷ µ¶¼º, Ç×ü ÀÇÁ¸¼º ¼¼Æ÷ ¸Å°³¼º ¼¼Æ÷ µ¶¼º
  • antibody-drug-cell complex
    Ç×ü ¾à¹° ¼¼Æ÷ º¹ÇÕü
  • antigen binding cell
    Ç׿ø °áÇÕ ¼¼Æ÷
    Ç׿ø¿¡ ´ëÇÑ Æ¯ÀÌÀûÀÎ °áÇձ⸦ ¼¼Æ÷ Ç¥¸é¿¡ °¡Áö°í ÀÖÀ¸¸ç Ç׿øÀ» ¼¼Æ÷ Ç¥¸é¿¡ °áÇÕ½ÃŰ´Â ´É·ÂÀ» °¡Áø ¼¼Æ÷. B ¼¼Æ÷ ¹× ÀϺÎÀÇ T ¼¼Æ÷°¡ Ç׿ø °áÇÕ ¼¼Æ÷¿¡ ÇØ´çµÈ´Ù. À̵éÀÇ ¸²ÇÁ±¸ÀÇ ¼¼Æ÷ Ç¥¸é¿¡ Ç׿øÀÌ °áÇյǾî ÀÖ´Â »óŸ¦ °¢Á¾ ¹æ¹ýÀ¸·Î È®ÀÎÇÒ ¼ö ÀÖ´Ù. Ç׿øÀ» ¹æ»ç¼º ¹°Áú·Î Ç¥ÁöÇØ µÎ°í autoradiogra
  • antitumor k cell
    Ç×Á¾¾ç k ¼¼Æ÷
  • anucleate cell
    ¹«ÇÙ ¼¼Æ÷
    ÇüÅÂÀûÀ¸·Î ºÐÈ­ÇÑ ±¸Á¶·Î¼­ÀÇ ÇÙÀ» °¡ÁöÁö ¾Ê´Â ¼¼Æ÷. ¼¼±ÕÀ̳ª ³²Á¶·ù¿¡¼­´Â ÇüÅÂÀûÀ¸·Î ¶Ñ·ÇÇÏ°Ô ºÐÈ­ÇÑ ÇÙÀÌ ¾ø´Ù. ÀÌ·¯ÇÑ ¼¼Æ÷¸¦ ÇÁ·ÎÄ«¸®¿ÀÆ®
  • APUD cell
    APUD ¼¼Æ÷
    amine
  • arsenical basal cell carcinoma
    ºñ¼Ò¼º ±âÀú¼¼Æ÷ ¾Ï
  • B cell
    B ¼¼Æ÷
    °ñ¼ö¿¡¼­ Çü¼ºµÈ ¸²ÇÁ±¸, ÇüÁú ¼¼Æ÷·Î ÀüȯµÇ¾î Ç×ü¸¦ »ý¼º. ÃéÀåÀÇ ¶û°Ô¸£Çѽº ¼¶¿¡ ÀÖ´Â 4Á¾·ùÀÇ ¼¼Æ÷ Áß Çϳª·Î¼­ Àν¶¸°À» ºÐºñÇÑ´Ù.
  • B cell clone
    B ¼¼Æ÷ Ŭ·Ð
    Ŭ·ÐÀ̶õ ´ÜÀÏÀÇ ¼¼Æ÷¸¦ Á¶»óÀ¸·Î ÇÏ´Â 1±ºÀÇ ¼¼Æ÷¸¦ ¸»ÇÑ´Ù. µû¶ó¼­ B ¼¼Æ÷ Ŭ·ÐÀº ´ÜÀÏÀÇ B ¼¼Æ÷°¡ ºÐ¿­, Áõ½ÄÇÏ¿© Çü¼ºÇÑ B ¼¼Æ÷ Áý´ÜÀ» ¸»ÇÑ´Ù. ÀÌ °æ¿ì µ¿ÀÏÇÑ ¸é¿ª ±Û·ÎºÒ¸° V À¯ÀüÀÚ¸¦ ¹ßÇöÇϰí ÀÖ´Â B ¼¼Æ÷·Î »ý°¢ÇÒ ¼ö ÀÖ´Ù. Á¤»óÀÇ B¼¼Æ÷´Â ¾Æ´ÏÁö¸¸ ¼¼Æ÷À¶ÇÕ¹ýÀ¸·Î ¾ò¾îÁø B ¼¼Æ÷ À¶ÇÕÁ¾µµ ¶Ç B¼¼Æ÷ Ŭ·ÐÀ̶ó°í ºÒ¸®¿ì´Â ¼ö°¡ ÀÖ´Ù.
  • B cell lymphoma
    B ¼¼Æ÷ ¸²ÇÁÁ¾
    ¾Ç¼º ¸²ÇÁÁ¾ Áß¿¡¼­ ¥ì¼â, DR Ç׿ø, Leu-10ÀÇ B ¸²ÇÁ±¸ Ç¥½ÃÀÚ°¡ Áõ¸íµÈ ¸²ÇÁÁ¾ÀÌ´Ù. Áõ¸íµÈ Ç¥½ÃÀÚ´Â °³°³ÀÇ Áõ·Ê¿¡ µû¶ó ´Ù¸£°í ¥ì+, DR+ Leu-10+ÀÇ ÀüÇüÀûÀÎ ¿¹·ÎºÎÅÍ DR ³»Áö Leu-10¸¸ÀÌ ¾ç¼ºÀÎ Áõ·Ê¿¡ À̸£±â±îÁö ±× º¯È­´Â ´Ù¾çÇÏ´Ù. ÇüÅÂÀûÀÎ ºÐ·ù¿¡ ÀÇÇÑ °áÀý¼º ¸²ÇÁÁ¾, ¸²ÇÁÇüÁú ¼¼Æ÷¼º ¸²ÇÁÁ¾, ¹èÁ᫐ ¼¼Æ÷¿¡¼­ À¯·¡ÇÏ´Â ¸²ÇÁÁ¾, Burkitt ¸²ÇÁÁ¾ µîÀÌ B¼¼Æ÷ ¸²ÇÁÁ¾¿¡ ¼ÓÇÑ´Ù.
  • B cell stimulating factor 1
    B ¼¼Æ÷ ÃËÁø ÀÎÀÚ 1
    µ¿ÀǾî´Â Interleukin 4·Î ¾Ë·ÁÁø ´ç´Ü¹éÀ¸·Î¼­ T ¼¼Æ÷, ºñ¸¸¼¼Æ÷ µî¿¡¼­ »ý»êµÈ´Ù. À̰ÍÀº B ¼¼Æ÷¿¡ ´ëÇØ comitogenÀ¸·Î ÀÛ¿ëÇϴµ¥ ±× ¿µÇâÀº B ¼¼Æ÷ÀÇ ¼º¼÷µµ¿¡ µû¶ó ´Ù¸£´Ù.
  • B cell tolerance
    B ¼¼Æ÷ ³»¼º
    ¸é¿ªÇÐÀû ³»¼º »óÅ´ T ¼¼Æ÷¿¡µµ B ¼¼Æ÷¿¡µµ ¹ß»ý ¼ö ÀÖÁö¸¸ B ¼¼Æ÷ÀÇ ³»¼º »óÅ´ T ¼¼Æ÷¿¡ ºñÇÏ¿© ¹ß»ýÇϱⰡ ¾î·Æ´Ù. B ¼¼Æ÷¸¦ ³»¼º »óÅ·ΠÇÏ·Á¸é ÀϹÝÀûÀ¸·Î ´ë·®ÀÇ Ç׿øÀÌ ÇÊ¿äÇϰí Ç׿ø Åõ¿© ÈÄ¿¡ ³»¼º »óÅ·Πµé¾î°¡´Â µ¥µµ T ¼¼Æ÷º¸´Ù ¿À·£ ½Ã°£ÀÌ °É¸®°í ÀÏ´Ü ³»¼º »óÅ·Πµé¾î°¡µµ Áö¼Ó½Ã°£ÀÌ Âª°í °ð ÇØÁ¦µÇ¾î ¹ö¸°´Ù.
  • band cell
    ¶ì ¼¼Æ÷
  • basal cell
    ±âÀú ¼¼Æ÷, ±âÃÊ ¼¼Æ÷
    Ç¥ÇÇ ±âÀúÃþ¿¡ Á¸ÀçÇÏ´Â Ãʱâ ÄÉ¶óÆ¾ ¼¼Æ÷¸¦ ÀÏÄ´ À̸§. Æ÷À¯·ù Á¤¼ÒÀÇ ¼¼Á¤°ü ¼Ó¿¡¼­ ¿ÜÃø ±âÀú¸·¿¡ Á¢ÇÏ¿© »êÀçÇØ ÀÖ´Â ´ëÇü ¼¼Æ÷. ¼¼¸£Å縮 ¼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
predisposing factors Attitudinal, personality, and related factors that motivate and guide an individual to take certain health actions.
(05 Mar 2000)
sex factors Maleness or femaleness as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or effect of a circumstance. It is used with human or animal concepts but should be differentiated from sex characteristics, anatomical or physiological manifestations of sex, and from sex distribution, the number of males and females in given circumstances.
(12 Dec 1998)
socioeconomic factors Social and economic factors that characterise the individual or group within the social structure.
(12 Dec 1998)
steam conversion factors (approximations) 1 pound of steam = 1,000 Btu = .3 kW. 10,000 lbs/hr steam = 300 boiler horsepower.
(05 Dec 1998)
debranching factors Enzyme's that bring about destruction of branches in glycogen; formerly considered to be one enzyme, now known to be a mixture of transferases (4-alpha-d-glucanotransferase) and hydrolases (amylo-1,6-glucosidase).
Synonym: debranching factors.
(05 Mar 2000)
suppressor factors, immunologic Proteins, protein complexes, or glycoproteins secreted by suppressor T-cells that inhibit either subsequent T-cells, B-cells, or other immunologic phenomena. Some of these factors have both histocompatibility (I-j) and antigen-specific domains which may be linked by disulfide bridges. They can be elicited by haptens or other antigens and may be mass-produced by hybridomas or monoclones in the laboratory.
(12 Dec 1998)
direct lytic factors most abundant proteins in cobra (naja of the elapids) venom; basic polypeptides of 57 to 62 amino acids with four disulfide bonds and a molecular weight of less than 7000; causes skeletal and cardiac muscle contracture, interferes with neuromuscular and ganglionic transmission, depolarises nerve, muscle and blood cell membranes, thus causing haemolysis.
Synonym: cobramine a; cobramine b; cobra cytotoxin; gamma toxin; membrane-active polypeptide.
(12 Dec 1998)
immunologic and biological factors A collective grouping for biologically active substances that play a role in the functioning of the immune system and those that show biological or physiological activity.
(12 Dec 1998)
immunologic factors Biologically active substances whose activities affect or play a role in the functioning of the immune system.
(12 Dec 1998)
initiation factors The set of catalytic proteins required, in addition to mRNA and ribosomes, for protein synthesis to begin. In bacteria three distinct proteins have been identified: if 1 (8 kD), IF 2 (75 kD) and IF 3 (30 kD). at least 6-8 proteins have been identified in eukaryotes. IFs 1 and 2 enhance the binding of initiator tRNA to the initiation complex.
(18 Nov 1997)
ischemia-modifying factors Various factors that play a role in determining the extent of necrosis with cerebral stroke; these include blood viscosity and osmolality, the blood pressure, and the anatomy of the neck and intracranial arteries.
(05 Mar 2000)
oesophageal carcinoma risk factors <radiology> P Plummer-Vinson Web, A achalasia, alcohol, B Barrett oesophagus, S stricture, T tylosis, tobacco see: oesophageal carcinoma
(12 Dec 1998)
thyroid carcinoma risk factors <radiology> Increased risk of malignancy: young female, male, history of radiation to head or neck, hard lesion, other neck masses, no shrinkage on TSH, family hx of thyroid carcinoma see: thyroid carcinoma
(12 Dec 1998)
time factors Elements of limited time intervals, contributing to particular results or situations.
(12 Dec 1998)
transcription factors Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • wet cell
    ½ÀÀüÁö
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á